Work

Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e18553

Authors: Daniel R Stellato, Lisa McGarry, Hui Huang, Shaina Hastings, Thomas E. Delea

Institutions: Policy Analysis (United States), ARIAD Pharmaceuticals (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890848874

Cites:

Cited by:

Related to: 10